The Ivy Brain Tumor Center at Barrow Neurological Institute announced the opening of a Phase 0 clinical trial for patients with newly diagnosed and recurrent glioblastoma to evaluate pamiparib, an investigational small molecule PARP inhibitor from BeiGene.
[The Ivy Brain Tumor Center (GlobeNewswire, Inc.)]
6445212
{6445212:nan}
apa
50
1
157333
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
